Aclarion, Inc. announced that CEO Brent Ness will attend LSI USA 2026, a premier conference for MedTech innovators, investors, and industry leaders scheduled for March 16-20, 2026 in Dana Point, California. During the conference, Ness will meet with investors and potential partners to discuss Aclarion's progress with Nociscan, the company's proprietary magnetic resonance spectroscopy platform. Nociscan represents a significant advancement in addressing chronic low back pain, a condition affecting millions worldwide.
The platform leverages biomarkers and proprietary augmented intelligence algorithms to help physicians distinguish between painful and non-painful discs in the lumbar spine. This distinction is crucial because current diagnostic methods often struggle to pinpoint the exact source of pain, leading to suboptimal treatment outcomes. By noninvasively identifying which discs may be causing pain, Nociscan provides physicians with critical insights to optimize treatment strategies. The technology works by receiving magnetic resonance spectroscopy data from MRI machines through a cloud connection, with proprietary signal processing techniques extracting and quantifying chemical biomarkers associated with disc pain.
This biomarker data is analyzed using AI algorithms to indicate whether a disc may be a source of pain. When used alongside other diagnostic tools, Nociscan offers physicians greater clarity in determining appropriate treatment approaches for patients suffering from chronic low back pain. LSI USA 2026 serves as an important platform for Aclarion to showcase this technology to the broader MedTech community, bringing together key stakeholders who can help accelerate the adoption of innovative healthcare solutions. For those seeking more information about Aclarion's technology, additional details about Nociscan are available through the company's website at https://www.aclarion.com.
The development of precise diagnostic tools for chronic low back pain has substantial implications for healthcare systems and patients alike. More accurate diagnosis could lead to more targeted treatments, potentially reducing unnecessary procedures and improving patient outcomes. As healthcare continues to embrace technological solutions, platforms like Nociscan demonstrate how AI and biomarker analysis can address longstanding challenges in medical diagnosis and treatment planning. The company also maintains a newsroom where updates are regularly posted at https://tinyurl.com/aconnewsroom.
